Clinical Impact of Upfront Dose Reduction of the First Cycle of First‐Line Treatments on Safety and Survival in Elderly Patients With Non‐Small Cell Lung Cancer
Asia-Pacific Journal of Clinical Oncology · 2026
DOI: 10.1111/ajco.14203 ↗Kurz gefasst
Fachartikel in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, 2026. Verfasst von Takashi Nojiri und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Thoracic Surgery, Higashiosaka City Medical Center, Higashiosaka-City, Osaka, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 19 Literaturangaben.
Abstract (Originalsprache)
Background
The number of elderly patients with non‐small cell lung cancer (NSCLC) is rapidly increasing worldwide. Elderly patients with NSCLC are less suited to active treatment than younger patients. Upfront dose reduction (UDR) of the first cycle of first‐line treatment is sometimes chosen for elderly patients due to adverse events. We investigated the clinical impact of UDR in elderly NSCLC patients.
Methods
From a prospective database of consecutive NSCLC patients without actionable genomic alterations who received first‐line treatment between November 2018 and March 2024, we analyzed 131 patients of ≥65 years of age. Patients were treated with standard‐dose chemotherapy between November 2018 and December 2021 and UDR chemotherapy between January 2022 and March 2024. We retrospectively compared the incidence of adverse events and clinical outcomes between the standard‐dose and UDR groups.
Results
The incidence of treatment‐related death was relatively lower in the UDR group (UDR vs. standard‐dose: 3.0 vs. 13.6%; p = 0.0624). There was no significant difference in the incidence of immune‐related adverse events between the two groups. The objective response rate was higher in the UDR group (UDR vs. standard‐dose: 61.5 vs. 48.5%; p = 0.161). The log‐rank analysis showed that the UDR group had significantly longer median progression‐free survival/overall survival relative to the standard‐dose group.
Conclusions
UDR as a first‐line treatment was safe and could be a suitable approach for elderly patients with NSCLC. Further research is needed to evaluate the clinical outcomes in the treatment of elderly NSCLC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of General Thoracic Surgery, Higashiosaka City Medical Center, Higashiosaka-City, Osaka, Japan.
- Department of Clinical Oncology, Higashiosaka City Medical Center, Higashiosaka-City, Osaka, Japan.
- Department of Thoracic Oncology, Kansai Medical University, Hirakata-City, Osaka, Japan.
Zitieren
APA
Nojiri, T., Omura, A., Iede, K., Katsushima, U., & Higashiyama, M. (2026). Clinical Impact of Upfront Dose Reduction of the First Cycle of First‐Line Treatments on Safety and Survival in Elderly Patients With Non‐Small Cell Lung Cancer. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.14203
Vancouver
Nojiri T, Omura A, Iede K, Katsushima U, Higashiyama M. Clinical Impact of Upfront Dose Reduction of the First Cycle of First‐Line Treatments on Safety and Survival in Elderly Patients With Non‐Small Cell Lung Cancer. Asia-Pacific Journal of Clinical Oncology. 2026. doi:10.1111/ajco.14203
BibTeX
@article{Nojiri2026,
author = {Nojiri, Takashi and Omura, Akiisa and Iede, Kiyotsugu and Katsushima, Utae and Higashiyama, Masahiko},
title = {Clinical Impact of Upfront Dose Reduction of the First Cycle of First‐Line Treatments on Safety and Survival in Elderly Patients With Non‐Small Cell Lung Cancer},
journal = {Asia-Pacific Journal of Clinical Oncology},
year = {2026},
doi = {10.1111/ajco.14203}
}
EUVIMED